中华皮肤科杂志 ›› 2020, Vol. 53 ›› Issue (5): 317-318.doi: 10.35541/cjd.20200283

• 专家笔谈 •    下一篇

新型冠状病毒肺炎疫情期间银屑病患者使用生物制剂的指导意见

王刚1,顾恒2,郑敏3,赵邑4,顾军5,晋红中6,刘晓明7,史玉玲8,孙青9   

  1. 1. 第四军医大学西京医院皮肤科
    2. 中国医学科学院北京协和医学院皮肤病研究所
    3. 杭州：浙江大学医学院附属第二医院
    4. 北京清华长庚医院
    5. 同济大学附属第十人民医院医院皮肤科；海军军医大学长海医院皮肤科
    6. 中国医学科学院北京协和医学院北京协和医院
    7. 香港大学深圳医院皮肤科
    8. 上海市第十人民医院
    9. 济南山东大学齐鲁医院皮肤科
  • 收稿日期:2020-03-23 修回日期:2020-03-30 发布日期:2020-04-30
  • 通讯作者: 王刚；顾恒 E-mail:xjwgang@fmmu.edu.cn; guheng@aliyun.com

Guidance on the use of biologic agents in psoriatic patients during COVID-19 outbreak

Wang Gang1, Gu Heng2, Zheng Min3, Zhao Yi4, Gu Jun5, Jin Hongzhong6, Liu Xiaoming7, Shi Yuling8, Sun Qing9   

  1. 1Department of Dermatology, Xijing Hospital, The Fourth Military Medical University, Xi′an 710032, China;  2Hospital for Skin Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing 210042, China; 3Department of Dermatology, The Second Affiliated Hospital of Zhejiang University School of Medcine, Hangzhou 310009, China;  4Department of Dermatology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing 102218, China;  5Department of Dermatology, Tenth People′s Hospital of Tongji University, Shanghai 200000, China; 6Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China;  7Department of Dermatology, The University of Hong Kong-Shenzhen Hospital, Shenzhen 518053, China;  8Shanghai Skin Diseases Hospital, Shanghai 200443, China;  9Department of Dermatology, Qilu Hospital of Shandong University, Jinan 250012, China
  • Received:2020-03-23 Revised:2020-03-30 Published:2020-04-30
  • Contact: Wang Gang; Gu Heng E-mail:xjwgang@fmmu.edu.cn; guheng@aliyun.com

PDF

29

PDF (Mobile)

4

摘要： 【摘要】 新型冠状病毒肺炎疫情对银屑病患者使用生物制剂可能产生一定的影响，生物制剂的免疫抑制作用可能改变患者对病毒的易感性或造成感染者病情加重，甚至影响预后。参考国际银屑病学术组织和专家的建议，结合我国实际情况，分别针对正在进行生物制剂治疗和拟进行生物制剂治疗的银屑病患者、高风险和低风险患者以及合并或不合并新型冠状病毒感染的患者提出了使用生物制剂的指导性建议，供临床实践中参考。

关键词: 新型冠状病毒肺炎, 新型冠状病毒, 银屑病, 生物制剂

Abstract: 【Abstract】 The COVID-19 outbreak may have a certain impact on the use of biologics in psoriatic patients, in the way that immunosuppressive effects of biologics may potentially alter the susceptibility of patients to the virus, deteriorate the condition of infected patients or even change the prognosis of infection. According to currently available recommendations from international psoriasis academic organizations and specialists, as well as specific situation in China, the authors provide some guidance on the use of biologics for psoriatic patients undergoing or planning to undergo treatment with biologics, those with low or high risk of infection, and for those with or without COVID-19 infection, so as to provide references for clinical practice.

Key words: COVID-19, SARS-CoV-2, Psoriasis, Biologic agents